Mark Goldberger, MD; Henry Masur, MD
Goldberger M, Masur H. Clarithromycin Therapy for Mycobacterium avium Complex Disease in Patients with AIDS: Potential and Problems. Ann Intern Med. 1994;121:974-976. doi: 10.7326/0003-4819-121-12-199412150-00012
Download citation file:
Published: Ann Intern Med. 1994;121(12):974-976.
The quality and duration of survival for patients with human immunodeficiency virus (HIV) infection have improved substantially during the past decade. Much of this improvement has been because of better management of opportunistic infections. However, progress with Mycobacterium avium complex, a pathogen that ultimately infects 30% to 50% of patients with the acquired immunodeficiency syndrome (AIDS) in North America, has until recently been disappointing, especially in terms of prophylaxis and therapy.
The development of new rifamycin and macrolide antibiotics has increased optimism among health care providers and patients searching for remedies for disease caused by this Mycobacterium species. Rifabutin, a newer rifamycin, has been approved by the U.S. Food and Drug Administration for prophylaxis of M. avium complex based on two large, controlled trials . Clarithromycin, a newer macrolide, is the only drug that has been approved to date for the acute treatment of disseminated M. avium complex disease. This approval was based largely on unpublished data (2, 3; Minutes of the Open Public Meeting of the Food and Drug Administration Antiviral Advisory Committee, 10 May 1993). For health care professionals and patients, an important question is, “Do we truly have therapy that can produce sustained clinical benefit?”
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only